I don't underdose my patients...do I? (Q81132586)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

I don't underdose my patients...do I? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

637-638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

How to calculate the dose of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970296-5

7 January 2021

10.1016/S1470-2045(05)70296-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16129364%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference